For the myotwin team, networking with industry partners was at the forefront. Numerous encounters with representatives from both industry and the start-up scene opened up new perspectives and confirmed myotwin’s growing role within the international biotech ecosystem. A particular highlight was reconnecting with colleagues from the EXIST funding program, including the team from immuneAdvice GmbH.
Participation in BIO-Europe Spring marks another step in myotwin’s international positioning. The company is already preparing for its next major milestones: the upcoming MPS World Summit in Brussels and the BIO International Convention in Boston this June, where myotwin will once again present its platform to a global audience and build on the partnerships initiated in Milan.
About myotwin
myotwin is a biotech company specializing in human–relevant, preclinical testing systems for the development of cardiovascular drugs. With its proprietary myoScreen platform, myotwin enables the simultaneous measurement of contraction force, tissue stiffness, calcium dynamics, and electrical activity—directly on human heart tissue.
As a next step, myotwin is developing myoAI, a digital twin of the heart muscle that uses artificial intelligence to predict the efficacy and toxicity of drugs. This is giving rise to a new generation of precise, data-driven drug development.
The Germany-based company works closely with research institutions, industry partners, and investors to advance innovative therapies for cardiovascular diseases more quickly and in a more targeted manner. For more information, visit www.myotwin.com.
Forward–looking statements
This communication may contain forward–looking statements based on current assumptions and forecasts made by myotwin’s management. Various known and unknown risks, uncertainties, and other factors could cause the actual results, financial position, development, or performance of the company to differ materially from the estimates given here. These factors include those described in myotwin’s public reports, which are available on the myotwin website at www.myotwin.com. The company assumes no obligation to update such forward-looking statements or to adapt them to future events or developments.
